Description: <b>Nimbolide</b> is a compound found in the neem tree (Azadirachta indica) and has been studied for its potential anti-cancer properties. nimbolide is a neem-derived tetranortriterpenoid limonoid from Azadirachta indica.<br>
<br>
Research has shown that nimbolide has anti-proliferative and pro-apoptotic effects on various types of cancer cells, including breast, lung, colon, and prostate cancer cells. It has also been shown to inhibit the growth of cancer cells by inducing cell cycle arrest and apoptosis (programmed cell death).<br>
<br>
Some of the ways in which nimbolide may help to prevent or treat cancer include:<br>
-Inhibiting the activity of certain enzymes that are involved in cancer cell growth and survival<br>
-Inducing the production of reactive oxygen species (ROS) that can damage cancer cells<br>
-Inhibiting the formation of new blood vessels that are needed to support the growth of cancer cells<br>
-Enhancing the effectiveness of chemotherapy and radiation therapy<br>
<p><b>Nimbolide</b> — Nimbolide is a neem-derived tetranortriterpenoid limonoid from <i>Azadirachta indica</i> with preclinical anticancer activity across multiple tumor models. It is best classified as a small-molecule plant limonoid / electrophilic triterpenoid natural product rather than as “neem oil” or whole neem extract. Standard abbreviation is NB or NL. aliases: “neem limonoids,” “neem extract,” and “Azadirachta indica limonoids” </p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Covalent modulation of the ubiquitin-proteasome axis, especially RNF114-dependent substrate recognition and p21 stabilization.</li>
<li>Mitochondrial oxidative stress induction through ROS elevation and SOD2 suppression in susceptible cancer cells.</li>
<li>Apoptosis activation through caspase signaling, mitochondrial stress, and survival-pathway suppression.</li>
<li>STAT3 and NF-κB pathway inhibition, reducing inflammatory survival signaling, proliferation, invasion, and anti-apoptotic transcription.</li>
<li>EMT, migration, invasion, angiogenesis, and metastasis suppression in preclinical models.</li>
<li>Autophagy modulation, including inhibition of cytoprotective autophagy in some tumor contexts.</li>
<li>DNA damage response leverage, including RNF114-linked PARP1 trapping and reported synthetic-lethality relevance in BRCA-mutated models.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Nimbolide is hydrophobic and poorly water-soluble, so systemic translation is constrained by formulation, solubility, exposure, metabolism, and tissue delivery. Nanoparticle and carrier-based formulations are being explored preclinically to improve delivery and anticancer exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer findings use purified nimbolide in cell culture or animal models; direct equivalence to oral neem preparations is not established. Common in-vitro low-micromolar activity should not be assumed achievable with dietary or crude neem exposure. Whole neem oil or extract is chemically heterogeneous and may not deliver predictable nimbolide exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical. Evidence is strong enough for a database entry as a mechanistically interesting anticancer natural product, but not as a clinically validated anticancer therapy. No approved oncology indication or clear nimbolide-specific cancer trial status was identified; clinical use should be treated as unsupported outside research contexts.</p>
<h3>Nimbolide Cancer Mechanism Table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>RNF114 ubiquitin ligase axis</td>
<td>RNF114 substrate recognition ↓; p21 stabilization ↑; proliferation ↓</td>
<td>Likely context-dependent; selectivity depends on dependency on RNF114-regulated substrates</td>
<td>R/G</td>
<td>Cell-cycle suppression and targeted-protein-degradation relevance</td>
<td>High mechanistic importance because nimbolide has a defined electrophilic target interaction and can be used as a covalent recruiter scaffold.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial ROS and SOD2</td>
<td>ROS ↑; SOD2 ↓; mitochondrial stress ↑; apoptosis ↑</td>
<td>Potential oxidative-stress risk at sufficient exposure; selectivity is model-dependent</td>
<td>R/G</td>
<td>Oxidative apoptosis and metastasis suppression</td>
<td>Core in pancreatic cancer models; may be especially relevant where tumor cells depend on antioxidant buffering.</td>
</tr>
<tr>
<td>3</td>
<td>Apoptosis and caspase activation</td>
<td>Caspase 3 ↑; caspase 8 ↑; caspase 9 ↑; survival ↓</td>
<td>Lower effect reported in some normal-cell comparisons, but not universally established</td>
<td>G</td>
<td>Programmed cell death induction</td>
<td>Central downstream phenotype across many cancer models.</td>
</tr>
<tr>
<td>4</td>
<td>STAT3 inflammatory survival signaling</td>
<td>STAT3 phosphorylation ↓; anti-apoptotic transcription ↓; invasion ↓</td>
<td>Could suppress normal inflammatory or repair signaling if systemic exposure is high</td>
<td>R/G</td>
<td>Reduced proliferation, survival, and metastatic signaling</td>
<td>Important in prostate and pancreatic cancer contexts; likely intersects with ROS and NF-κB effects.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB and Wnt beta catenin</td>
<td>NF-κB activation ↓; IκB degradation ↓; Wnt beta catenin signaling ↓</td>
<td>Potential immune and epithelial-homeostasis effects are context-dependent</td>
<td>R/G</td>
<td>Anti-inflammatory, anti-survival, and anti-proliferative signaling</td>
<td>Broadly reported in neem/nimbolide literature, but pathway dominance varies by tumor model.</td>
</tr>
<tr>
<td>6</td>
<td>Autophagy survival axis</td>
<td>Cytoprotective autophagy ↓; apoptosis ↑</td>
<td>Autophagy effects may be protective or harmful depending on tissue stress state</td>
<td>G</td>
<td>Removal of tumor stress-adaptation capacity</td>
<td>Secondary but therapeutically relevant where autophagy supports tumor survival.</td>
</tr>
<tr>
<td>7</td>
<td>EMT migration invasion metastasis</td>
<td>EMT markers ↓; migration ↓; invasion ↓; metastatic traits ↓</td>
<td>Could affect normal wound-healing pathways at sufficient exposure</td>
<td>G</td>
<td>Anti-metastatic phenotype</td>
<td>Strong preclinical relevance; not yet clinically validated.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis</td>
<td>Pro-angiogenic signaling ↓</td>
<td>Physiologic angiogenesis may be affected in repair contexts</td>
<td>G</td>
<td>Reduced tumor vascular support</td>
<td>Best treated as secondary/contextual unless a specific cancer model demonstrates angiogenesis as the dominant effect.</td>
</tr>
<tr>
<td>9</td>
<td>PARP1 trapping and BRCA synthetic lethality</td>
<td>PARP1 trapping ↑; BRCA-mutated vulnerability ↑</td>
<td>DNA repair stress possible in proliferating normal cells</td>
<td>R/G</td>
<td>DNA-repair vulnerability exploitation</td>
<td>Mechanistically interesting and industry-relevant, but narrower than the general ROS and ubiquitin-ligase mechanisms.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro potency does not guarantee tumor exposure; formulation-dependent activity</td>
<td>Safety margin uncertain for systemic use; crude neem products are not equivalent to purified nimbolide</td>
<td>G</td>
<td>Limits clinical interpretation</td>
<td>Major constraints are poor solubility, uncertain human PK, lack of oncology trials, botanical heterogeneity, and neem toxicity concerns.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>